Disease · MP_0001845

inflammation

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. inflammation. Diseases, record MP_0001845. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MP_0001845

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: inflammation; Open Targets
Open Targets ID: MP_0001845; Open Targets
Other names: inflammatory response; Open Targets
MeSH: D007249; MeSH
NCI Thesaurus: C3137; NCI Thesaurus
Highest stage of its drugs: Approval, for 62 of its 291 drugs, from DailyMed, PMDA and TTD; Open Targets

Drugs291

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	70	17	16	Drugs and targets
PREDNISOLONE ACETATE	CHEMBL1152	Small molecule	Approval	DailyMed	28	6	6	Drugs and targets
LOTEPREDNOL ETABONATE	CHEMBL1200865	Small molecule	Approval	DailyMed	12	5	5	Drugs and targets
DIFLUPREDNATE	CHEMBL1201749	Small molecule	Approval	DailyMed	5	4	4	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Approval	DailyMed	25	3	3	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Approval	PMDA	4	3	3	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed and TTD	6	2	2	Drugs and targets
HYDROCORTISONE	CHEMBL389621	Small molecule	Approval	DailyMed and TTD	30	1	1	Drugs and targets
TOBRAMYCIN	CHEMBL1747	Small molecule	Approval	DailyMed	16	1	1	Drugs and targets
KETOROLAC TROMETHAMINE	CHEMBL1201124	Small molecule	Approval	DailyMed	15	1	1	Drugs and targets

1 to 10 of 291

See all 291 drugs

Targets218

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	27	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS2	Cyclooxygenase	15	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	13	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	4	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
MAPK14	Mitogen-activated protein kinase 14	4	MAP kinase p38 alpha inhibitor	Phase 1	https://conductscience.org/library/genes/1432	Drugs and targets
ADRA1A	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
IL6	Interleukin-6	3	Interleukin-6 binding agent; Interleukin-6 inhibitor	Phase 2	https://conductscience.org/library/genes/3569	Drugs and targets
TYK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/7297	Drugs and targets

1 to 10 of 218

See all 218 targets

Trials124

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02786901	LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery	Phase 3	600	2020-04-14	Cataract, Pain, Ocular Inflammation	LOTEPREDNOL ETABONATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04393038	ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19	Phase 2/3	509	2025-11-26	COVID-19	OBEFAZIMOD	Its record names the disease	ClinicalTrials.gov
NCT03499873	Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension	Phase 3	448	2021-02-16	Cataract	NEPAFENAC	Its record names the disease	ClinicalTrials.gov
NCT00905450	Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery	Phase 2	415	2020-09-03	Cataract, Inflammation	MAPRACORAT	Its record names the disease	ClinicalTrials.gov
NCT01060072	Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery	Phase 3	407	2012-01-13	Inflammation, Pain	LOTEPREDNOL ETABONATE	Its record names the disease	ClinicalTrials.gov
NCT00645671	Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery	Phase 3	400	2010-09-23	Ocular Inflammation	LOTEPREDNOL ETABONATE	Its record names the disease	ClinicalTrials.gov
NCT00699153	Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery	Phase 3	400	2010-09-23	Ocular Inflammation	LOTEPREDNOL ETABONATE	Its record names the disease	ClinicalTrials.gov
NCT00521456	A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery	Phase 3	263	2009-10-01	Cataract Extraction	KETOROLAC	Its record names the disease	ClinicalTrials.gov
NCT03192137	Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery	Phase 3	260	2020-06-29	Inflammation and Pain Associated With Cataract Surgery	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT04246801	Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)	Phase 3	250	2022-12-22	Cataract	CLOBETASOL PROPIONATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 124

See all 124 trials

Comparisons in its trials58

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
ABX464 vs Placebo: deaths from any cause	6 of 335	4 of 170	505	NCT04393038	Trial comparisons
ABX464 vs Placebo: serious adverse events	36 of 335	20 of 170	505	NCT04393038	Trial comparisons
Loteprednol Etabonate vs Vehicle: Grade 0 Pain	156 of 206	92 of 201	407	NCT01060072	Trial comparisons
Loteprednol Etabonate vs Vehicle: Resolution of Anterior Chamber Cells.	64 of 206	28 of 201	407	NCT01060072	Trial comparisons
Loteprednol Etabonate vs Vehicle: serious adverse events	3 of 206	1 of 201	407	NCT01060072	Trial comparisons
Loteprednol Etabonate vs Vehicle: Participants With Grade 0 (no) Pain	149 of 203	83 of 202	405	NCT00699153	Trial comparisons
Loteprednol Etabonate vs Vehicle: Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0	64 of 203	23 of 202	405	NCT00699153	Trial comparisons
Loteprednol Etabonate vs Vehicle: serious adverse events	2 of 204	4 of 201	405	NCT00699153	Trial comparisons
Loteprednol Etabonate vs Vehicle: serious adverse events	3 of 201	2 of 199	400	NCT00645671	Trial comparisons
ABX464 vs Placebo: Rate of Patients Hospitalized	23 of 203	11 of 102	305	NCT04393038	Trial comparisons

1 to 10 of 58

See all 58 comparisons in its trials

Papers from its trials67

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37876758	RESULT	1	PubMed
35648294	RESULT	1	PubMed
35064813	RESULT	1	PubMed
33715258	RESULT	1	PubMed
31058771	RESULT	1	PubMed
29859160	RESULT	1	PubMed
28670710	RESULT	2	PubMed
27810317	RESULT	2	PubMed
25038357	RESULT	1	PubMed
24935281	RESULT	2	PubMed

1 to 10 of 67

See all 67 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MP_0001845

GET https://conductscience.org/api/diseases/v1/MP_0001845/drugs?page=2

API reference For AI assistants